ImmunityBio Inc 2024年度报告

About ImmunityBio ImmunityBio is a vertically-integrated commercial stage biotechnology company developingnext-generation therapies and vaccines that bolster the natural immune system to defeatcancers and infectious diseases. The Company’s range of immunotherapy platforms, alone andtogether, act to drive an immune response with the goal of creating durable immune memorygenerating safe protection against disease. We are applying our science and platforms totreating cancers, including the development of potential cancer vaccines, as well as developingimmunotherapies and cell therapies that we believe sharply reduce or eliminate the need forstandard high-dose chemotherapy. These platforms and their associated product candidatesare designed to be more effective, accessible, and easily administered than current standards ofcare in oncology and infectious diseases. For more information, visit ImmunityBio.com(Founder’s Vision) and connect with us on X (Twitter), Facebook, LinkedIn, and Instagram. Our Approved Product – ANKTIVA® The cytokine interleukin-15 (IL-15) plays a crucial role in the immune system by affecting thedevelopment, maintenance, and function of key immune cells—NK and CD8+ killer T cells—thatare involved in killing cancer cells. By activating NK cells, ANKTIVA overcomes the tumorescape phase of clones resistant to T cells and restores memory T cell activity with resultantprolonged duration of complete response. ANKTIVA is a first-in-class IL-15 receptor superagonist IgG1 fusion complex, consisting of anIL-15 mutant (IL-15N72D) fused with an IL-15Rα, which binds with high affinity to IL-15receptors on NK, CD4+, and CD8+ T cells. This fusion complex of ANKTIVA, which confersstability and longer half-life than recombinant or native IL-15, mimics the natural biologicalproperties of the membrane-bound IL-15Rα, delivering IL-15 by dendritic cells and drives theactivation and proliferation of NK cells with the generation of memory killer T cells that haveretained immune memory against these tumor clones. The proliferation of the trifecta of theseimmune killing cells and the activation of trained immune memory results in immunogenic celldeath, inducing a state of equilibrium with durable complete responses. ANKTIVA has improvedpharmacokinetic properties, longer persistence in lymphoid tissues, and enhanced anti-tumoractivity compared to native, non-complexed IL-15 in-vivo. ANKTIVA was approved by the FDA in 2024 for use in the United States with BCG for thetreatment of adult patients with BCG-unresponsive non-muscle invasive bladder cancer withCIS with or without papillary tumors. For more information, visit ImmunityBio.com (Founder’sVision) and Anktiva.com. UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549FORM 10-K (Mark One) ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 or IMMUNITYBIO, INC. (Exact name of registrant as specified in its charter) Registrant’s telephone number, including area code: (844) 696-5235 Securities registered pursuant to Section 12(b) of the Act: Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. YesþNo¨ Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes¨Noþ Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Actof 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subjectto such filing requirements for the past 90 days. YesþNo¨ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant toRule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant wasrequired to submit such files). YesþNo¨ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reportingcompany, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and“emerging growth company” in Rule 12b-2 of the Exchange Act. If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying withany new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.¨ Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of itsinternal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accountingfirm that prepared or issued its audit